Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry

Abstract Introduction Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung function and overall survival (OS) in real-world cohorts on longer follow-up exists. Patients/methods Of the...

Full description

Bibliographic Details
Main Authors: Monika Zurkova, Eva Kriegova, Vitezslav Kolek, Vladimira Lostakova, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Ilona Binkova, Michal Svoboda, Jana Strenkova, Marketa Janotova, Martina Plackova, Ladislav Lacina, Vladimir Rihak, Frantisek Petrik, Pavlina Lisa, Radka Bittenglova, Richard Tyl, Gustav Ondrejka, Hana Suldova, Jaroslav Lnenicka, Jana Psikalova, Tomas Snizek, Jiri Homolka, Renata Kralova, Jan Kervitzer, Martina Vasakova, ILD section, IPF registry
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Respiratory Research
Subjects:
Idiopathic pulmonary fibrosis
Pirfenidone
Mortality prediction
Disease progression
Online Access:http://link.springer.com/article/10.1186/s12931-019-0977-2

Internet

http://link.springer.com/article/10.1186/s12931-019-0977-2

Similar Items